Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and Multiple Dose Study of MK-7480 in Healthy Japanese Participants
jRCT2071240015Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MK-7480 in metabolic dysfunction-associated steatotic liver disease (MASLD) (4 arms), sponsored by Merck & Co. Primary endpoint: Safety and tolerability of MK-7480. Started Jul 2024; status: completed.
02
Drugs
MK-7480
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on jRCT2071240015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240015.